Trials / Completed
CompletedNCT01601808
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 142 (actual)
- Sponsor
- University of Liverpool · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Orally once a day, continuously throughout the study |
| DRUG | Caprelsa (vandetanib) | Orally once a daily, continuously throughout the study. |
Timeline
- Start date
- 2011-10-10
- Primary completion
- 2018-09-05
- Completion
- 2018-09-05
- First posted
- 2012-05-18
- Last updated
- 2025-03-13
Locations
14 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01601808. Inclusion in this directory is not an endorsement.